Abstract
Abstract
Backgroud
Although not fully investigated, studies show that Legionella pneumophila can develop antibiotic resistance. As there is limited data available for Portugal, we determined the antibiotic susceptibility profile of Portuguese L. pneumophila serogroup 1 (LpnSg1) isolates against antibiotics used in the clinical practice in Portugal.
Methods
Minimum inhibitory concentrations (MICs) were determined for LpnSg1 clinical (n = 100) and related environmental (n = 7) isolates, collected between 2006–2022 in the context of the National Legionnaire´s Disease Surveillance Programme, against azithromycin, clarithromycin, erythromycin, levofloxacin, ciprofloxacin, moxifloxacin, rifampicin, doxycycline, tigecycline, and amoxicillin/clavulanic acid, using three different assays. Isolates were also PCR-screened for the presence of the lpeAB gene.
Results
Twelve isolates had azithromycin MICs above the EUCAST tentative highest WT MIC, 9 of which were lpeAB negative; for erythromycin and clarithromycin, all isolates tested within the susceptible range. The number of isolates with MICs above the tentative highest WT MIC for the remaining antibiotics was: ciprofloxacin: 7; levofloxacin: 17; moxifloxacin: 8; rifampicin: 11; doxycycline: 82; tigecycline: 4. EUCAST breakpoints are not available for amoxicillin/clavulanic acid. We estimated the ECOFFs and one isolate had a MIC eightfold higher than the E-test ECOFF. Additionally, a clinical isolate generated three colonies growing on the E-test inhibition zone that resulted in MICs fourfold higher than for the parental isolate.
Conclusions
We report, for the first time, elevated MICs against first-line and other antibiotics (including azithromycin, fluoroquinolones and amoxicillin/clavulanic acid commonly used to treat pneumonia patients in Portugal) in Portuguese L. pneumophila strains. Results point towards decreased susceptibility in circulating strains, justifying further investigation.
Funder
Instituto Nacional de Saúde Dr. Ricardo Jorge
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Cunha BA, Burillo A, Bouza E (2016) Legionnaires’ disease. Lancet 387:376–385
2. Beauté J, Plachouras D, Sandin S, Giesecke J, Sparén P (2020) Healthcare-associated legionnaires’ disease, Europe, 2008–2017. Emerg Infect Dis 26:2309–2318
3. European Centre for Disease Prevention and Control. Legionnaires´ Disease [Internet]. Surveillance Atlas of Infectious Diseases. Available at: https://atlas.ecdc.europa.eu/public/index.aspx. Accessed 21 July 2022
4. Shivaji T, Pinto CS, San-Bento A et al (2014) A large community outbreak of Legionnaires’ disease in Vila Franca de Xira, Portugal, October to November 2014. Eurosurveillance 19:20991
5. Faccini M, Russo AG, Bonini M et al (2020) (2020) Large community-acquired Legionnaires’ disease outbreak caused by Legionella pneumophila serogroup 1, Italy, July to August 2018. Euro Surveill. 25(20):1900523. https://doi.org/10.2807/1560-7917.ES.2020.25.20.1900523